CK5/6、CK14和CK34βE12免疫组化分析在乳腺导管内乳头状瘤伴普通型导管增生与实性原位乳头状癌鉴别诊断中的应用。
Use of immunohistochemical analysis of CK5/6, CK14, and CK34betaE12 in the differential diagnosis of solid papillary carcinoma in situ from intraductal papilloma with usual ductal hyperplasia of the breast.
作者信息
Maeda Ichiro, Tajima Shinya, Kanemaki Yoshihide, Tsugawa Koichiro, Takagi Masayuki
机构信息
Department of Pathology, St. Marianna University School of Medicine, Kawasaki, Japan.
Department of Radiology, St. Marianna University School of Medicine, Kawasaki, Japan.
出版信息
SAGE Open Med. 2018 Nov 9;6:2050312118811542. doi: 10.1177/2050312118811542. eCollection 2018.
OBJECTIVES
The aim of this study was to use immunohistochemistry to differentiate solid papillary carcinoma in situ from intraductal papilloma with usual ductal hyperplasia (IPUDH). Three types of high-molecular-weight cytokeratins (CKs) - CK5/6, CK14, and CK34betaE12 - were targeted.
METHODS
We studied 17 patients with solid papillary carcinoma in situ and 18 patients with IPUDH diagnosed by at least two pathologists. Immunohistochemical analyses used antibodies to CK5/6, CK14, and CK34betaE12 to make the differential diagnosis of solid papillary carcinoma in situ versus IPUDH. Immunohistochemical staining was scored as 0-5 using Allred score.
RESULTS
Immunohistochemistry with CK5/6 and CK14 antibodies produced scores of 0-3 in all patients with solid papillary carcinoma in situ and 2-5 in all patients with IPUDH. Immunohistochemical staining with CK34betaE12 antibody produced scores of 1-3 in all patients with solid papillary carcinoma and 3-5 in all patients with IPUDH. In tissues from patients with IPUDH, significantly more cells were stained with CK34betaE12 than CK5/6 ( < 0.05) or CK14 ( < 0.05).
CONCLUSION
The immunoreactivity of CK5/6, CK14, and CK34betaE12 antibodies was useful to differentiate solid papillary carcinoma in situ from IPUDH. CK34betaE12 is especially useful for distinguishing solid papillary carcinoma from IPUDH.
目的
本研究旨在利用免疫组织化学方法鉴别原位实性乳头状癌与伴有普通导管增生的导管内乳头状瘤（IPUDH）。研究针对三种高分子量细胞角蛋白（CKs）——CK5/6、CK14和CK34βE12。
方法
我们研究了17例经至少两名病理学家诊断为原位实性乳头状癌的患者以及18例诊断为IPUDH的患者。免疫组织化学分析使用针对CK5/6、CK14和CK34βE12的抗体，以对原位实性乳头状癌与IPUDH进行鉴别诊断。免疫组织化学染色采用Allred评分法，评分为0 - 5分。
结果
使用CK5/6和CK14抗体进行免疫组织化学检测时，所有原位实性乳头状癌患者的评分为0 - 3分，所有IPUDH患者的评分为2 - 5分。使用CK34βE12抗体进行免疫组织化学染色时，所有实性乳头状癌患者的评分为1 - 3分，所有IPUDH患者的评分为3 - 5分。在IPUDH患者组织中，被CK34βE12染色的细胞显著多于被CK5/6染色的细胞（<0.05）或被CK14染色的细胞（<0.05）。
结论
CK5/6、CK14和CK34βE12抗体的免疫反应性有助于鉴别原位实性乳头状癌与IPUDH。CK34βE12在区分实性乳头状癌与IPUDH方面尤其有用。
Zotero 插件